智通财经APP获悉，德琪医药-B(06996)盘中涨超12%，年内累计涨幅已超320%，截至发稿，涨9.92%，报2.77港元，成交额1684.13万港元。
消息面上，德琪医药宣布，印尼食品药品监督管理局(BPOM)已批准希维奥®(塞利尼索片)用于3项适应症的新药上市申请(NDA)。公司2月中旬宣布，自2025年3月1日起，希维奥获批纳入台湾全民健康保险。
值得注意的是，德琪医药近日公布，公司计划加大投入，整合资源成立专门的AI部门。这一举措包括本地部署DeepSeek以加速具有空间位元阻遮蔽效应的T细胞衔接器（TCE）平台后续管线研发。据悉，公司早在2021年便以天使投资人身份投资杭州德睿智药AI药物发现平台，并借此战略性的切入了AI药物发现赛道。同时公司也已通过AI资料模型结合多组学分析，成功发现全新肝癌相关抗原(TAA)并将其开发为TCE候选药物进入临床前验证阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.